Microglial TREM2 in amyotrophic lateral sclerosis. Issue 1 (18th December 2021)

• Record Type: Journal Article
• Authors: Xie, Manling; Zhao, Shunyi; Bosco, Dale B.; Nguyen, Aivi; Wu, Long‐Jun
• Is Part Of: Developmental neurobiology. Volume 82:Issue 1(2022)
• Page Start: 125
• Page End: 137
• Publication Date: 2021-12-18
• Subjects: amyotrophic lateral sclerosis -- disease‐associated microglia -- microglia -- TDP‐43 -- TREM2; Neurobiology -- Periodicals; Neurobiology; Neurobiologie -- Périodiques; Neurobiology; Periodicals; Periodicals; 573.838
• DOI: 10.1002/dneu.22864
• Languages: English
• ISSNs: 1932-8451

Abstract

Abstract: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is an aggressive motor neuron degenerative disease characterized by selective loss of both upper and lower motor neurons. The mechanisms underlying disease initiation and progression are poorly understood. The involvement of nonmotor neuraxis emphasizes the contribution of glial cells in disease progress. Microglia comprise a unique subset of glial cells and are the principal immune cells in the central nervous system (CNS). Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, within the CNS, is exclusively expressed on microglia and plays crucial roles in microglial proliferation, migration, activation, metabolism, and phagocytosis. Genetic evidence has linked TREM2 to neurodegenerative diseases including ALS, but its function in ALS pathogenesis is largely unknown. In this review, we summarize how microglial activation, with a specific focus on TREM2 function, affects ALS progression clinically and experimentally. Understanding microglial TREM2 function will help pinpoint the molecular target for ALS treatment.